Dosed ingredient Cosmetic cross-reference

Glycine

CAS 56-40-6

Glycine (CAS 56-40-6) is a Phase 4 pharmaceutical compound with 4 bioactivity targets and 42 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
8
SOURCE DrugCentral
Adverse signals
42
SOURCE IUPHAR/BPS
PubMed IDs
3
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Glycine
CAS Number
56-40-6
UNII
TE7660XO1C
InChIKey
DHMQDGOQFOQNFH-UHFFFAOYSA-N
ChEMBL ID
CHEMBL773
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL773 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 8 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 27454.503125 nM 32 -
- EC50 14817.866153846155 nM 12 -
- IC50 9733.468333333332 nM 11 -
- Ki 147.945 nM 2 -
Glutamate receptor ionotropic, NMDA 1
Ion channel
 IC50 6.6 - Rattus norvegicus
Sodium- and chloride-dependent glycine transporter 1
Transporter
 IC50 4.5 - Homo sapiens
Glutamate NMDA receptor
Ion channel
 Ki 6.77 - Rattus norvegicus
Olfactory receptor 51E2
GPCR
 EC50 7.24 - Homo sapiens
SOURCE DrugCentral 6 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Foetal growth restriction 15 57.797 10070531
Stevens-Johnson syndrome 16 45.87 10042033
Compartment syndrome 10 44.699 10010121
Vasoplegia syndrome 9 42.214 10067080
Device related sepsis 10 41.772 10069802
Infantile apnoea 8 40.621 10077321

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 7 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
GPRC6
GPRC6A
 Full agonist 3.6 pEC50 15576628
GluN1
GRIN1
 Agonist - -
GluN2A
GRIN2A
 Agonist - -
GluN2B
GRIN2B
 Agonist - -
GluN2C
GRIN2C
 Agonist - -
GluN2D
GRIN2D
 Agonist - -
Glycine Receptor (All subtypes) Agonist 4.3 pEC50 8404844|9009272
SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Glycine 4919 SU MTHSPL
GLYCINE 4919 SU MTHSPL
glycine 4919 SU MTHSPL
glycine 4919 IN RXNORM
SOURCE SIDER 73 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Acidosis glycine LLT C0001122
Acidosis glycine PT C0001122
Angina pectoris glycine LLT C0002962
Angina pectoris glycine PT C0002962
Back pain glycine LLT C0004604
Back pain glycine PT C0004604
Blindness transient glycine LLT C0155003
Blindness transient glycine PT C0155003
Cardiovascular disorder glycine LLT C0007222
Cardiovascular disorder glycine PT C0007222
Chills glycine LLT C0085593
Chills glycine PT C0085593
Coma glycine LLT C0009421
Coma glycine PT C0009421
Convulsion glycine LLT C0036572
Convulsion glycine PT C0036572
Dehydration glycine LLT C0011175
Dehydration glycine PT C0011175
Diarrhoea glycine LLT C0011991
Diarrhoea glycine PT C0011991
Digitalis toxicity glycine LLT C0012254
Disorders of fluid, electrolyte and acid-base balance glycine LLT C0267994
Diuresis glycine LLT C0012797
Dizziness glycine PT C0012833
Electrolyte imbalance glycine PT C0342579
Encephalopathy glycine LLT C0085584
Encephalopathy glycine PT C0085584
Fluid overload glycine LLT C0546817
Fluid overload glycine PT C0546817
Hyperammonaemia glycine LLT C0220994
Hyperammonaemia glycine PT C0220994
Hypersensitivity glycine LLT C0020517
Hypersensitivity glycine PT C0020517
Hyponatraemia glycine LLT C0020625
Hyponatraemia glycine PT C0020625
Hypotension glycine LLT C0020649
Hypotension glycine PT C0020649
Lightheadedness glycine LLT C0220870
Lung disorder glycine LLT C0024115
Lung disorder glycine PT C0024115
Nausea glycine LLT C0027497
Nausea glycine PT C0027497
Oedema glycine LLT C0013604
Oedema glycine PT C0013604
Pain glycine LLT C0030193
Pain glycine PT C0030193
Polyuria glycine PT C0032617
Pulmonary congestion glycine LLT C0242073
Pulmonary congestion glycine PT C0242073
Respiratory tract congestion glycine PT C0948349
Rhinitis glycine LLT C0035455
Rhinitis glycine PT C0035455
Salivary hypersecretion glycine PT C0037036
Salivation glycine LLT C0036104
Tachycardia glycine LLT C0039231
Tachycardia glycine PT C0039231
Thirst glycine LLT C0039971
Thirst glycine PT C0039971
Thrombophlebitis glycine LLT C0040046
Thrombophlebitis glycine PT C0040046
Toxicity to various agents glycine PT C3160741
Urinary retention glycine LLT C0080274
Urinary retention glycine PT C0080274
Urticaria glycine LLT C0042109
Urticaria glycine PT C0042109
Vertigo glycine LLT C0042571
Vertigo glycine PT C0042571
Vision blurred glycine LLT C0344232
Vision blurred glycine PT C0344232
Visual disturbance glycine LLT C0547030
Visual impairment glycine PT C3665347
Vomiting glycine LLT C0042963
Vomiting glycine PT C0042963
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Glycine used for in pharmaceutical contexts?

Glycine (CAS 56-40-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Glycine?

Glycine has 42 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Stevens-Johnson syndrome, Compartment syndrome, Vasoplegia syndrome, Device related sepsis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Glycine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Glycine with EU status "permitted".

What clinical phase is Glycine in?

Glycine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Glycine?

Glycine has 8 bioactivity rows in this page query. Rendered target entries include Glutamate receptor ionotropic, NMDA 1, Sodium- and chloride-dependent glycine transporter 1, Glutamate NMDA receptor, Olfactory receptor 51E2.